OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Holdings in Rezolute, Inc. (NASDAQ:RZLT)

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Rezolute, Inc. (NASDAQ:RZLT - Free Report) by 19.8% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 526,223 shares of the company's stock after purchasing an additional 86,990 shares during the period. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.91% of Rezolute worth $2,578,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. JPMorgan Chase & Co. purchased a new position in shares of Rezolute in the 3rd quarter worth $42,000. Charles Schwab Investment Management Inc. boosted its stake in shares of Rezolute by 65.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 22,757 shares of the company's stock worth $112,000 after buying an additional 9,000 shares during the last quarter. American Century Companies Inc. boosted its stake in shares of Rezolute by 62.1% in the 4th quarter. American Century Companies Inc. now owns 64,591 shares of the company's stock worth $316,000 after buying an additional 24,742 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Rezolute by 5.2% in the 4th quarter. Geode Capital Management LLC now owns 517,014 shares of the company's stock worth $2,535,000 after buying an additional 25,413 shares during the last quarter. Finally, ExodusPoint Capital Management LP purchased a new position in shares of Rezolute in the 4th quarter worth $277,000. 82.97% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the company. Wedbush restated an "outperform" rating and issued a $12.00 price target on shares of Rezolute in a research note on Wednesday. Guggenheim restated a "buy" rating on shares of Rezolute in a research note on Monday, February 10th. JMP Securities upped their price objective on Rezolute from $8.00 to $9.00 and gave the stock a "market outperform" rating in a research note on Thursday, February 13th. HC Wainwright restated a "buy" rating and issued a $14.00 price objective on shares of Rezolute in a research note on Monday, April 28th. Finally, Craig Hallum upgraded Rezolute to a "strong-buy" rating in a research note on Tuesday, February 4th. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $12.14.

Rezolute Price Performance

Shares of NASDAQ:RZLT traded up $0.01 during midday trading on Friday, hitting $3.57. The company had a trading volume of 1,113,556 shares, compared to its average volume of 629,641. Rezolute, Inc. has a 12-month low of $2.22 and a 12-month high of $6.19. The company has a market cap of $216.11 million, a price-to-earnings ratio of -2.93 and a beta of 1.01. The company has a fifty day moving average of $3.24 and a two-hundred day moving average of $4.30.

Rezolute (NASDAQ:RZLT - Get Free Report) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.05). Research analysts expect that Rezolute, Inc. will post -0.93 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Rezolute news, CFO Daron Evans purchased 10,000 shares of the business's stock in a transaction on Wednesday, March 26th. The stock was acquired at an average price of $2.89 per share, for a total transaction of $28,900.00. Following the purchase, the chief financial officer now owns 237,900 shares of the company's stock, valued at approximately $687,531. This represents a 4.39% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Nevan C. Elam purchased 12,302 shares of the business's stock in a transaction on Thursday, March 27th. The stock was acquired at an average price of $2.85 per share, with a total value of $35,060.70. Following the purchase, the chief executive officer now directly owns 224,119 shares in the company, valued at $638,739.15. This represents a 5.81% increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders acquired 39,060 shares of company stock worth $130,694. Corporate insiders own 18.39% of the company's stock.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.